Early-onset and Late-onset Sporadic Alzheimer's Disease (AD)

Early-onset and Late-onset Sporadic Alzheimer's Disease (AD) : Variations of the Clinical Profile and Paraclinical Features Depending on the Age at the Onset of Clinical Signs

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00987090

Enrollment

240

Registered

2009-09-30

Start date

2009-10-31

Completion date

Unknown

Last updated

2015-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Keywords

subjects developing symptoms of Alzheimer Disease

Brief summary

Alzheimer's disease (AD) is usually associated with aging, age being the principal identified risk factor. However, younger subjects also develop AD and the prevalence of early onset AD is unknown. It is estimated that about 30 000 subjects develop symptoms of AD before the age of 65 in France. There is evidence that early onset AD differs from AD in older patients. In particular, clinical and neuroimaging studies suggest early involvement of neocortical brain regions and their functions in early onset AD, while mediotemporal areas and memory might be more involved in late onset AD. These differences could partly explain the atypical clinical and imaging features of younger patients, the diagnostic difficulties in these patients and the specific problems related to medical care of this age group. The present study uses a multidisciplinary approach with longitudinal followup in order to establish the impact of age on the clinical and neuroimaging picture of sporadic AD in a multicentric setting. Another aim of the project is to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.

Interventions

BIOLOGICALClinic and neuropsychologic evaluation

evaluation at the inclusion and 18 months after

RADIATIONMRI

intervention at the inclusion and 18 months after

PROCEDUREPET

18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.

BIOLOGICALApolipoprotein E genotyping

genotyping at the inclusion

BIOLOGICALStudy of cerebrospinal fluid

intervention at the inclusion

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

45 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* Arm Alzheimer Disease : first symptoms from 1 to 5 years before the inclusion, Clinical Dementia Rating = 1, efficient contraception for women * Arm Control : efficient contraception for women

Exclusion criteria

* Important general disease : diabetes, neoplasia, alcoholism * First symptoms less than 1 year or more than 5 years before the inclusion * Pregnancy, breast feeding

Design outcomes

Primary

Measure	Time frame
to establish the impact of age on the clinical and neuroimaging picture of sporadic Alzheimer Disease in a multicentric setting.	3 years

Secondary

Measure	Time frame
to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.	3 years

Countries

France

Contacts

Primary ContactMathieu Ceccaldi

mathieu.ceccaldi@ap-hm.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026